Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 8/20 | 0.42 |
| ▸ | F12 | P00748 | 7/20 | 0.42 |
| ▸ | HRAS | P01112 | 4/20 | 0.39 |
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16693618 | 0.80 | BACE1 (0.48) | BACE1MAOBF12RAB9ANPC1 | |
| SCHEMBL18407966 | 0.78 | BACE1 (0.56) | BACE1MAOBRAB9ANPC1ALDH1A1 | |
| SCHEMBL21727504 | 0.77 | BACE1 (0.58) | BACE1MAOBRAB9ANPC1THRB | |
| SCHEMBL26725622 | 0.76 | HRAS (0.51) | BACE1HRASESR1ESR2RAB9A | |
| SCHEMBL16693581 | 0.76 | BACE1 (0.48) | BACE1MAOBRAB9ANPC1THRB | |
| SCHEMBL20581209 | 0.73 | HRAS (0.49) | MAOBF12HRASESR1ESR2 | |
| SCHEMBL22564872 | 0.72 | GRM4 (0.52) | BACE1MAOBALDH1A1 | |
| SCHEMBL16693559 | 0.72 | RAB9A (0.54) | RAB9ANPC1THRBALDH1A1MAPT | |
| SCHEMBL20581348 | 0.72 | HRAS (0.49) | HRASESR1ESR2RAB9ANPC1 | |
| SCHEMBL26725555 | 0.71 | BACE1 (0.48) | BACE1RAB9ANPC1THRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321774-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | CHRM1, CHRM2, CHRM3 | BACE1 3215/4885MAOB 513/4885F12 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.